Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Dow hits record high on tame inflation report that also boosts small caps
U.S.-listed shares of Chinese firms such as Alibaba (NYSE: BABA) rose 2.8%, PDD Holdings climbed 4.4% and NetEase (NASDAQ: ...
Le Lézard34m
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased to announce the publication of positive findings in a peer-reviewed paper in the Journal of Medical Virology ...
New schizophrenia drug ‘could change the lives of millions of people’
A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
MM&M48m
Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Stock market today: Wall Street drifts around its records as Chinese stocks close a monster week
U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of ...
MedPage Today1h
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...